Navigation Links
/C O R R E C T I O N -- Nycomed/
Date:9/10/2009

In the news release, "First Results From Major European Patient Survey Show Devastating Impact of Living With Breakthrough Cancer Pain" issued on 9 Sep 2009 07:00 GMT, by Nycomed over PR Newswire, we are advised by a representative of the company that the first set of bullet points should read "The median number of BTCP episodes per patient per day was 3; Each episode had a median duration of 60 minutes; 96% of the pain episodes were described as moderate to severe; For 90% of patients their BTCP interfered with their daily living including their ability to sleep, walk and get on with other people" and the second set of bullet points should read "At least 95% of patients were using orally administered drugs; "The time to first noticing a reduction in pain had a median time of 20 minutes; In this survey the median time to peak effect of the current BTCP rescue medications was 30 minutes". In addition, the fourth paragraph should read "For this kind of pain episode the ideal treatment would be fast acting with a short duration of action to most closely match the nature of BTCP episodes" instead of "For this kind of pain episode the ideal treatment would be fast acting with short duration of action to most closely match the nature of BTCP episodes" as incorrectly transmitted by PR Newswire. Complete, corrected release follows:

, /PRNewswire/ --

- Choosing a More Appropriate Route of Administration for Fast Acting Pain Relief Could be the key to Improvement

The first results of the first European survey of cancer patients' experience of breakthrough pain[1] were presented today at the 6th congress of the European Federation of Chapters of the International Association for the Study of Pain (EFIC).

(Logo: http://www.newscom.com/cgi-bin/prnh/20090909/358726 )

Previous surveys have looked at the overall management of pain in cancer patients but this is the first international study to look in detail at Breakthrough Cancer Pain (BTCP) from a patient perspective. These results for the first 200 patients from the UK, Sweden and Denmark offer valuable insight into cancer patients' experiences with breakthrough pain management and the impact of the condition on their daily lives.

    - The median number of BTCP episodes per patient per day was 3

    - Each episode had a median duration of 60 minutes

    - 96% of the pain episodes were described as moderate to severe

    - For 90% of patients their BTCP interfered with their daily living
      including their ability to sleep, walk and get on with other people

"The study documents that breakthrough pain has a significant impact on cancer patients' daily lives," explained Dr. Andrew Davies, Department of Palliative Medicine, Royal Marsden Hospital, UK and the principal investigator of this survey. "Breakthrough pain is very different to background pain. Background pain is a continuous, chronic pain requiring around-the-clock medication. Breakthrough pain is a fast onset, short duration, intense pain that breaks through the chronic pain even when this is being controlled with medication. It is incapacitating and very distressing to the patient."

For this kind of pain episode the ideal treatment would be fast acting with a short duration of action to most closely match the nature of BTCP episodes. Moreover, it must be easy to use to improve patient compliance. However, the results of the survey show that:

    - At least 95% of patients were using orally administered drugs
    - The time to first noticing a reduction in pain had a median time of
      20 minutes
    - In this survey the median time to peak effect of the current BTCP
      rescue medications was 30 minutes

"Oral opioids are still commonly used to manage BTCP despite the fact that the way these drugs work does not match the characteristics of a BTCP episode. Opioids given by other routes, for example intranasal, have significant advantages over oral opioids and the interim results from this survey suggest that these routes would be suitable for and welcomed by the majority of cancer patients with breakthrough pain," said Dr. Andrew Davies.

The European Survey of Breakthrough Cancer Pain is continuing to recruit patients in Germany and Ireland and will expand into Austria, Belgium, Czech Republic, Finland, France, Greece, the Netherlands, Norway, Portugal, Spain and Switzerland to provide health care professionals across Europe with patient insights on the management of breakthrough cancer pain.

About Nycomed

Nycomed is a privately owned global pharmaceutical company with a differentiated portfolio focused on branded medicines in gastroenterology, respiratory and inflammatory diseases, pain, osteoporosis and tissue management. An extensive range of OTC products completes the portfolio. Its R&D is built to be open for partnerships as in-licensing is a cornerstone in the company's growth strategy.

Nycomed employs 12,000 associates worldwide, and its products are available in more than 100 countries. It has strong platforms in Europe and in fast-growing markets such as Russia/CIS, and Latin America. While the US and Japan are commercialised through best-in-class partners, Nycomed will further strengthen its position in key Asian markets.

Headquartered in Zurich, Switzerland, the company generated in 2008 total sales of EUR 3.4 billion and an adjusted EBITDA of EUR 1.2 billion.

For more information please visit http://www.nycomed.com

References

1. Davies A et al. European survey of oncology patient's experience of breakthrough cancer pain: UK, SE and DK results. Poster presented at EFIC 2009.

    About the survey

    - First phase of an ongoing, multicentre observational study

    - First five countries include: UK, Sweden, Denmark, Germany, Ireland

    - 11 palliative care units

    - 400 patients with breakthrough cancer pain

    - Data collected on breakthrough cancer pain and treatment of
      breakthrough cancer pain

    - First results are based on 200 patients from UK (80), Sweden (80) and
      Denmark (40)

    - The study is supported by an educational grant from Nycomed.

For further information:

Media: Ulf Jonson, Senior International Brand Manager, Nycomed: +45-46-77-10-78

------

First Results From Major European Patient Survey Show Devastating Impact of Living With Breakthrough Cancer Pain

LISBON, Portugal, September 9 /PRNewswire/ --

- Choosing a More Appropriate Route of Administration for Fast Acting Pain Relief Could be the key to Improvement

The first results of the first European survey of cancer patients' experience of breakthrough pain[1] were presented today at the 6th congress of the European Federation of Chapters of the International Association for the Study of Pain (EFIC).

(Logo: http://www.newscom.com/cgi-bin/prnh/20090909/358726 )

Previous surveys have looked at the overall management of pain in cancer patients but this is the first international study to look in detail at Breakthrough Cancer Pain (BTCP) from a patient perspective. These results for the first 200 patients from the UK, Sweden and Denmark offer valuable insight into cancer patients' experiences with breakthrough pain management and the impact of the condition on their daily lives.

    - On average each patient had 3 episodes of BTCP per day

    - Each episode had an average duration of 60 minutes

    - 96% of the pain episodes were described as moderate to severe

    - For 87% of patients their BTCP interfered with their daily living
      including their ability to sleep, walk and get on with other people

"The study documents that breakthrough pain has a significant impact on cancer patients' daily lives," explained Dr. Andrew Davies, Department of Palliative Medicine, Royal Marsden Hospital, UK and the principal investigator of this survey. "Breakthrough pain is very different to background pain. Background pain is a continuous, chronic pain requiring around-the-clock medication. Breakthrough pain is a fast onset, short duration, intense pain that breaks through the chronic pain even when this is being controlled with medication. It is incapacitating and very distressing to the patient."

For this kind of pain episode the ideal treatment would be fast acting with short duration of action to most closely match the nature of BTCP episodes. Moreover, it must be easy to use to improve patient compliance. However, the results of the survey show that:

    - 98% of patients were using orally administered drugs
    - The time to first noticing a reduction in pain was on average 20
      minutes
    - The time to knowing that the pain medication was really making a
      difference was on average 30 minutes or half way through the typical
      BTCP episode observed in this survey

"Oral opioids are still commonly used to manage BTCP despite the fact that the way these drugs work does not match the characteristics of a BTCP episode. Opioids given by other routes, for example intranasal, have significant advantages over oral opioids and the interim results from this survey suggest that these routes would be suitable for and welcomed by the majority of cancer patients with breakthrough pain," said Dr. Andrew Davies.

The European Survey of Breakthrough Cancer Pain is continuing to recruit patients in Germany and Ireland and will expand into Austria, Belgium, Czech Republic, Finland, France, Greece, the Netherlands, Norway, Portugal, Spain and Switzerland to provide health care professionals across Europe with patient insights on the management of breakthrough cancer pain.

About Nycomed

Nycomed is a privately owned global pharmaceutical company with a differentiated portfolio focused on branded medicines in gastroenterology, respiratory and inflammatory diseases, pain, osteoporosis and tissue management. An extensive range of OTC products completes the portfolio. Its R&D is built to be open for partnerships as in-licensing is a cornerstone in the company's growth strategy.

Nycomed employs 12,000 associates worldwide, and its products are available in more than 100 countries. It has strong platforms in Europe and in fast-growing markets such as Russia/CIS, and Latin America. While the US and Japan are commercialised through best-in-class partners, Nycomed will further strengthen its position in key Asian markets.

Headquartered in Zurich, Switzerland, the company generated in 2008 total sales of EUR 3.4 billion and an adjusted EBITDA of EUR 1.2 billion.

For more information please visit http://www.nycomed.com

References

1. Davies A et al. European survey of oncology patient's experience of breakthrough cancer pain: UK, SE and DK results. Poster presented at EFIC 2009.

    About the survey

    - First phase of an ongoing, multicentre observational study

    - First five countries include: UK, Sweden, Denmark, Germany, Ireland

    - 11 palliative care units

    - 400 patients with breakthrough cancer pain

    - Data collected on breakthrough cancer pain and treatment of
      breakthrough cancer pain

    - First results are based on 200 patients from UK (80), Sweden (80) and
      Denmark (40)

    - The study is supported by an educational grant from Nycomed.

For further information:

Media: Ulf Jonson, Senior International Brand Manager, Nycomed: +45-46-77-10-78


'/>"/>
SOURCE Nycomed
Copyright©2009 PR Newswire.
All rights reserved

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/13/2016)... ... 13, 2016 , ... Valentine’s Day is nearly upon us, and most singles ... great outfit, flawless hair, and a sparkling personality are all well and good, but ... night at home with Rover. (Actually, man’s best friend might not even want to ...
(Date:2/13/2016)... ... February 13, 2016 , ... Many individuals looking to lead a healthy lifestyle ... reasons. IsoPasta by Isolator Fitness has delved into this niche allowing those giving ... high-carb repercussions. IsoPasta has 30 grams of protein and only 7 grams of ...
(Date:2/13/2016)... ... February 13, 2016 , ... The producers of Enterprises TV are ... The increasingly modern world of instantaneous consumption proves very convenient for businesses. With new ... oil and coal, which pollutes our air, water, and soil. It can also threaten ...
(Date:2/13/2016)... ... February 13, 2016 , ... Christie Medical Holdings, Inc. presented ... a VeinViewer® Vision vein finder for the nursing school simulation lab. ... and draw blood, combining technology with traditional technique. , “VeinViewer is a wonderful ...
(Date:2/13/2016)... (PRWEB) , ... February 13, 2016 , ... In the ... forward. They’ll groom themselves to perfection, go out of their way to be romantic, ... – just take a look at any online dating profile. , A recent ...
Breaking Medicine News(10 mins):
(Date:2/12/2016)... FRAMINGHAM, Mass. , Feb. 12, 2016   ... scheduled a conference call and webcast to discuss its ... December 31, 2015, on Thursday, February 25, 2016 at ... financial results prior to the conference call and webcast.  ... the company,s financial results, highlights from the fourth quarter ...
(Date:2/12/2016)...  Memorial Hermann Health System has teamed up with ... bring a one-of-a-kind experience to pediatric patients at ... as 360-degree video and Google Cardboard, Howard was able ... giving the patients and their families an unexpected, and ... on video . Memorial Hermann IRONMAN ...
(Date:2/12/2016)... SEOUL, South Korea , Feb. 12, 2016 ... today announced they will form a partnership to ... medicine in cancer. The goal of the collaboration ... with Macrogen,s high-throughput Next Generation Sequencing capabilities toward ... Laboratory Improvement Amendments (CLIA) of 1988 by the ...
Breaking Medicine Technology: